<DOC>
	<DOCNO>NCT00006364</DOCNO>
	<brief_summary>Phase II trial study effectiveness homoharringtonine treat patient chronic phase chronic myelogenous leukemia . Drugs use chemotherapy , homoharringtonine , work different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>Homoharringtonine Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose homoharringtonine patient transform phase chronic myelogenous leukemia ( CML ) . ( Phase I complete 2/11/2004 . ) II . Determine toxicity profile drug patient . III . Determine response duration patient chronic phase CML treat drug . IV . Compare pharmacokinetics drug administer continuous infusion v subcutaneously patient . OUTLINE : This pilot , dose-escalation study . ( Phase I complete 2/11/2004 . ) Remission induction therapy : Patients receive remission induction therapy comprise homoharringtonine IV continuously 24 hour day 1 subcutaneously ( SC ) twice daily day 2-14 course 1 . Subsequent course remission induction therapy comprise homoharringtonine SC twice daily day 1-14 . Treatment continue monthly least 2 course . Maintenance therapy : Patients complete hematologic remission receive maintenance therapy comprise homoharringtonine SC twice daily day 1-7 monthly 3 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos homoharringtonine maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . An additional cohort 25-30 patient chronic phase chronic myelogenous leukemia receive remission induction maintenance therapy MTD . ( Phase I complete 2/11/2004 . ) Patients follow every 3 month . PROJECTED ACCRUAL : A maximum 50 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>Diagnosis chronic phase chronic myelogenous leukemia ( CML ) , define follow : Less 15 % blast peripheral blood ( PB ) bone marrow ( BM ) Less 20 % basophil PB BM Platelet count &gt; 100,000/mm^3 ( unless relate therapy ) Absence clonal evolution* Philadelphia chromosome OR BCR/ABLpositive disease cytogenetics , fluorescence situ hybridization , polymerase chain reaction Failed prior therapy imatinib mesylate , define follow : Failed achieve lose complete hematologic remission 3 month therapy Failed achieve lose least minimal cytogenetic response 6 month therapy Failed achieve lose major complete cytogenetic response 12 month therapy Unable tolerate imatinib mesylate despite adequate dose adjustment Failed 2 prior treatment regimen ( addition imatinib mesylate ) Treatment hydroxyurea consider one regimen Ineligible know regimen protocols high efficacy priority Performance status Zubrod 02 At least 2 month Bilirubin great 2.0 mg/dL Creatinine le 2.0 mg/dL No New York Heart Association class III IV heart disease Not pregnant nursing Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>